Completed PHASE4 INTERVENTIONAL 3-arm NCT00539526

Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues

Sponsor: Allergan

Conditions Ocular Hypertension Open Angle Glaucoma

Interventions Bimatoprost 0.03% latanoprost 0.005% eye drops travoprost 0.004%

Updated 9 times since 2017 Last updated: Apr 10, 2019 Started: Sep 30, 2007 Primary completion: Jul 31, 2008 Completion: Sep 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Ocular Hypertension and Open Angle Glaucoma and is currently completed. Allergan leads this study, which shows 9 recorded versions since 2007 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4
Jan 2021 — Dec 2022 [monthly]

Completed PHASE4

▶ Show 4 earlier versions

May 2019 — Jan 2021 [monthly]

Completed PHASE4
Jun 2018 — May 2019 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allergan

Data source: Allergan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Diego, United States